Literature DB >> 26293220

[Development of telemedical solutions based on the electronic case record (EFA)].

W Deiters1, S Houta2.   

Abstract

Efficient communication among doctors who cooperatively support their patients is a prerequisite for implementing effective intersectoral treatment processes. In order to achieve this, IT is becoming increasingly important. With IT systems doctors want to exchange information concerning a patient's case (e.g. doctors' letters, medication prescriptions, etc.). Furthermore, more and more IT-based applications that support the treatment process between patient and doctor (e.g. telemedicine solutions) are being developed. The development of the electronic case record (elektronische FallAkte) has yielded concepts and solutions for a structured case-based information exchange. Furthermore, it has led to infrastructure solutions that support service-based applications for telemedical applications. The "elektronische FallAkte" is an initiative of health institutions that have been organized into the association "Verein elektronische FallAkte". In this paper, concepts and realizations of the "elektronische FallAkte", as well as service-based applications on that infrastructure are described.

Entities:  

Keywords:  Electronic case record; Integrating the Healthcare Enterprise (IHE); Intersectoral treatment processes; Telemedicine

Mesh:

Year:  2015        PMID: 26293220     DOI: 10.1007/s00103-015-2221-7

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  2 in total

1.  [Primary Health Care in Austria - Tu Felix Austria nube - Concept for networking in the primary care of Upper Austria].

Authors:  Johannes Kriegel; Erwin Rebhandl; Wolfgang Hockl; Anna-Maria Stöbich
Journal:  Wien Med Wochenschr       Date:  2016-11-22

Review 2.  [Strategies for digitalizing the hospital of the future].

Authors:  W Deiters; A Burmann; S Meister
Journal:  Urologe A       Date:  2018-09       Impact factor: 0.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.